ATE359771T1 - Pellets mit venlafaxin-hydrochlorid - Google Patents
Pellets mit venlafaxin-hydrochloridInfo
- Publication number
- ATE359771T1 ATE359771T1 AT04791654T AT04791654T ATE359771T1 AT E359771 T1 ATE359771 T1 AT E359771T1 AT 04791654 T AT04791654 T AT 04791654T AT 04791654 T AT04791654 T AT 04791654T AT E359771 T1 ATE359771 T1 AT E359771T1
- Authority
- AT
- Austria
- Prior art keywords
- pellets
- weight
- venlafaxine hydrochloride
- chloride
- venlafaxine
- Prior art date
Links
- 239000008188 pellet Substances 0.000 title abstract 4
- 229960002416 venlafaxine hydrochloride Drugs 0.000 title abstract 3
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical compound [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 title abstract 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0303382A HUP0303382A2 (hu) | 2003-10-10 | 2003-10-10 | Venlafaxin-hidroklorid-tartalmú pelletek |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE359771T1 true ATE359771T1 (de) | 2007-05-15 |
Family
ID=90001704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04791654T ATE359771T1 (de) | 2003-10-10 | 2004-10-08 | Pellets mit venlafaxin-hydrochlorid |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1677777B1 (de) |
| CN (1) | CN1882321B (de) |
| AT (1) | ATE359771T1 (de) |
| AU (1) | AU2004280132B2 (de) |
| BG (1) | BG109539A (de) |
| CY (1) | CY1106693T1 (de) |
| CZ (1) | CZ2006269A3 (de) |
| DE (1) | DE602004006009T2 (de) |
| DK (1) | DK1677777T3 (de) |
| EA (1) | EA009695B1 (de) |
| ES (1) | ES2285538T3 (de) |
| HR (2) | HRP20060136A2 (de) |
| HU (1) | HUP0303382A2 (de) |
| IL (1) | IL174830A (de) |
| NO (1) | NO20062082L (de) |
| PL (2) | PL379541A1 (de) |
| PT (1) | PT1677777E (de) |
| RS (2) | RS20060252A (de) |
| SI (1) | SI1677777T1 (de) |
| SK (1) | SK50442006A3 (de) |
| UA (1) | UA82268C2 (de) |
| WO (1) | WO2005034930A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| BR0115382A (pt) | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
| EP1906935A4 (de) * | 2005-07-28 | 2010-10-20 | Reddys Lab Ltd Dr | Venlafaxin-zusammensetzungen mit verlängerter freisetzung |
| EP2023903B1 (de) * | 2006-05-19 | 2014-04-23 | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság | Verfahren für die vorbereitung und oberflächenbeschichtung von tabletten |
| US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
| WO2011143119A1 (en) * | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcohol-resistant extended release dosage forms comprising venlafaxine |
| CA2798702A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholresistant metoprolol-containing extended-release oral dosage forms |
| US20160367502A1 (en) * | 2012-12-19 | 2016-12-22 | Ratiopharm Gmbh | Film coated pellets |
| CN103893151B (zh) * | 2012-12-31 | 2018-04-27 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸文拉法辛缓释胶囊及其制备方法 |
| US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
| WO2020225773A1 (en) | 2019-05-07 | 2020-11-12 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| CN114028577B (zh) * | 2021-10-20 | 2024-07-02 | 珠海市东辰制药有限公司 | 一种二氧化硅丸芯及其制备方法 |
| CN119868294A (zh) * | 2024-11-08 | 2025-04-25 | 迪沙药业集团有限公司 | 一种利格列汀药物组合物及制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE57198A1 (es) * | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
| EP1331003B1 (de) * | 1996-03-25 | 2015-08-26 | Wyeth LLC | Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe |
| UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
| CN1334080A (zh) * | 2001-07-25 | 2002-02-06 | 成都康弘制药有限公司 | 盐酸万拉法新缓释片及其制备方法 |
| IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
| WO2003082261A1 (en) * | 2002-03-28 | 2003-10-09 | Synthon B.V. | Extended release venlafaxine formulations |
-
2003
- 2003-10-10 HU HU0303382A patent/HUP0303382A2/hu unknown
-
2004
- 2004-08-10 UA UAA200605099A patent/UA82268C2/uk unknown
- 2004-10-08 EP EP04791654A patent/EP1677777B1/de not_active Expired - Lifetime
- 2004-10-08 PL PL379541A patent/PL379541A1/pl not_active IP Right Cessation
- 2004-10-08 RS YUP-2006/0252A patent/RS20060252A/sr unknown
- 2004-10-08 RS RS20060252A patent/RS52150B/sr unknown
- 2004-10-08 HR HR20060136A patent/HRP20060136A2/xx not_active Application Discontinuation
- 2004-10-08 CN CN2004800330326A patent/CN1882321B/zh not_active Expired - Fee Related
- 2004-10-08 ES ES04791654T patent/ES2285538T3/es not_active Expired - Lifetime
- 2004-10-08 DE DE602004006009T patent/DE602004006009T2/de not_active Expired - Lifetime
- 2004-10-08 AU AU2004280132A patent/AU2004280132B2/en not_active Ceased
- 2004-10-08 SI SI200430364T patent/SI1677777T1/sl unknown
- 2004-10-08 SK SK5044-2006A patent/SK50442006A3/sk unknown
- 2004-10-08 CZ CZ20060269A patent/CZ2006269A3/cs unknown
- 2004-10-08 HR HR20070322T patent/HRP20070322T3/xx unknown
- 2004-10-08 PL PL04791654T patent/PL1677777T3/pl unknown
- 2004-10-08 DK DK04791654T patent/DK1677777T3/da active
- 2004-10-08 AT AT04791654T patent/ATE359771T1/de active
- 2004-10-08 PT PT04791654T patent/PT1677777E/pt unknown
- 2004-10-08 EA EA200600675A patent/EA009695B1/ru not_active IP Right Cessation
- 2004-10-08 WO PCT/HU2004/000095 patent/WO2005034930A1/en not_active Ceased
-
2006
- 2006-04-06 IL IL174830A patent/IL174830A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062082A patent/NO20062082L/no unknown
- 2006-05-10 BG BG109539A patent/BG109539A/bg unknown
-
2007
- 2007-07-02 CY CY20071100874T patent/CY1106693T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL1677777T3 (pl) | 2007-08-31 |
| NO20062082L (no) | 2006-05-09 |
| SK50442006A3 (sk) | 2006-08-03 |
| RS20060252A (sr) | 2008-08-07 |
| HRP20070322T3 (hr) | 2007-09-30 |
| AU2004280132B2 (en) | 2009-10-22 |
| PL379541A1 (pl) | 2006-10-02 |
| DK1677777T3 (da) | 2007-09-03 |
| IL174830A0 (en) | 2008-04-13 |
| AU2004280132A1 (en) | 2005-04-21 |
| RS52150B (sr) | 2012-08-31 |
| DE602004006009T2 (de) | 2008-01-10 |
| SI1677777T1 (sl) | 2007-10-31 |
| UA82268C2 (uk) | 2008-03-25 |
| CZ2006269A3 (cs) | 2006-07-12 |
| HK1098364A1 (en) | 2007-07-20 |
| EA009695B1 (ru) | 2008-02-28 |
| CN1882321B (zh) | 2011-06-08 |
| PT1677777E (pt) | 2007-06-21 |
| HUP0303382D0 (en) | 2003-12-29 |
| EA200600675A1 (ru) | 2006-08-25 |
| IL174830A (en) | 2010-04-15 |
| HRP20060136A2 (en) | 2006-06-30 |
| WO2005034930A1 (en) | 2005-04-21 |
| EP1677777A1 (de) | 2006-07-12 |
| EP1677777B1 (de) | 2007-04-18 |
| ES2285538T3 (es) | 2007-11-16 |
| DE602004006009D1 (de) | 2007-05-31 |
| HUP0303382A2 (hu) | 2005-08-29 |
| CN1882321A (zh) | 2006-12-20 |
| BG109539A (bg) | 2006-11-30 |
| CY1106693T1 (el) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE359771T1 (de) | Pellets mit venlafaxin-hydrochlorid | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| SG153830A1 (en) | Galenic formulations of organic compounds | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| WO2009028495A1 (ja) | 真菌性皮膚炎用剤 | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| SG158168A1 (en) | 5ht2c receptor modulator compositions and methods of use | |
| EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
| ATE331525T1 (de) | Salzformarme polyallylamine | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| DK1711169T3 (da) | Coatede mikrodepottabletter med venlafaxinhydrochlorid | |
| EA201170784A1 (ru) | Гранулы тамсулозина для фиксированной комбинации | |
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| MY139086A (en) | Use of debranched starch in extrusion-spheronization pharmaceutical pellets | |
| MX2010003594A (es) | Formas cristalinas de sal sodica de dmxaa. | |
| EA200702496A1 (ru) | Местная композиция, содержащая желатин | |
| EA200500175A1 (ru) | Соль морфин-6-глюкуронида | |
| PL1589014T3 (pl) | Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli | |
| MY167609A (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| GR1004331B (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος | |
| HUP0303383A2 (hu) | Piridazinon-származékot tartalmazó pelletek | |
| UA115684C2 (uk) | Фармацевтична композиція для перорального застосування, що містить декскетопрофен та трамадол | |
| RU2006126471A (ru) | Способ лечения воспалительных заболеваний слюнных желез | |
| RU2006119994A (ru) | Противотуберкулезная фармацевтическая композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1677777 Country of ref document: EP |